BRCA1-IRIS Inactivation Overcomes Paclitaxel Resistance in Triple Negative Breast Cancers

Breast Cancer Research - United Kingdom
doi 10.1186/s13058-014-0512-9
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

BRCA1/2-negative Hereditary Triple-Negative Breast Cancers Exhibit BRCAness

International Journal of Cancer
Cancer ResearchOncology
2017English

Aurora Kinase a Stabilizes FOXM1 to Enhance Paclitaxel Resistance in Triple‐negative Breast Cancer

Journal of Cellular and Molecular Medicine
Molecular MedicineCell Biology
2019English

Molecular Stratification of Triple-Negative Breast Cancers

Oncologist
Cancer ResearchMedicineOncology
2010English

53BP1 Loss Rescues BRCA1 Deficiency and Is Associated With Triple-Negative and BRCA-mutated Breast Cancers

Nature Structural and Molecular Biology
Structural BiologyMolecular Biology
2010English

22p * Development of a Brca1-Like Signature in Triple Negative Breast Cancers Within the Rather (Rational Therapy for Breast Cancer) Consortium

Annals of Oncology
MedicineOncologyHematology
2014English

Transgelin: A Potentially Useful Diagnostic Marker Differentially Expressed in Triple-Negative and Non–triple-Negative Breast Cancers

Human Pathology
Forensic MedicinePathology
2015English

Nab-Paclitaxel for the Management of Triple-Negative Metastatic Breast Cancer

Anti-Cancer Drugs
Cancer ResearchOncologyPharmacology
2015English

Profiling Molecular Regulators of Recurrence in Chemorefractory Triple-Negative Breast Cancers

Breast Cancer Research
Cancer ResearchOncology
2019English

Genetic Variations in Triple-Negative Breast Cancers Undergoing Neo-Adjuvant Chemotherapy

2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy